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Kinetic studies of the pyruvate kinases of rat and human tissues have led to  the identification 
of three classes of isoenzymes with qualitative differences in regulatory properties. 
Class L, the major component in liver extracts and a minor component of kidney extracts, 
shows markedly sigmoidal kinetics with respect to the concentration of phosphoenolpyruvate, 
allosteric inhibition by ATP and alanine, and activation by fructose 1,6-bisphosphate. Class A, 
present in adipose tissue, and the major component in kidney and the minor one in liver, shows 
slightly sigmoidal substrate saturation curves and is allosterically inhibited by alanine and acti- 
vated by fructose 1,6-bisphosphate. Class M, present in muscle and brain, has none of the above 
regulatory properties. 
The activities of the pyruvate kinases of cIasses L and A respond immediately to  changes in 
the concentration of the effectors alanine and fructose 1,6-bisphosphate. 
The two regulatory isoenzymes are strongly inhibited by three amino acids : alanine, cysteine, 
and phenylalanine. Cysteine is the stronger inhibitor for class L, while phenylalanine is the stron. 
ger one for class A. The allosteric inhibition is stereospecific for the L-amino acids in contrast with 
the weak isosteric inhibition of muscle pyruvate kinase by L- or D-alanine as analogue of the 
product. 
The allosteric inhibition of pyruvate kinase L by ATP is highly specific in contrast with a 
rather wide specificity of this enzyme for nucleoside diphosphates as acceptor substrates. 
Evidence for the occurrence of several isoenzymes 
of pyruvate kinase in higher animals, particularly 
in the rat, has been reported from several laboratories 
[I--31. While most of the classifications have been 
based on electrophoretic evidence, a marked contrast 
in regulatory properties of the major component 
of pyruvate kinase activity in liver (“L”) with 
respect to the older known muscle enzyme (“M”) has 
also been amply demonstrated [2,4-81. A systematic 
screening for key kinetic properties of the pyruvate 
kinase activity in certain rat tissues and fractions, 
prompted by the interest in the physiological signif- 
icance of the potential control of the pyruvate kinase 
reaction in different types of metabolism, has given 
results which indicate that there are a t  least three 
classes of isoenzymes of pyruvate kinase differing in 
regulatory properties in rat and human tissues: the 
highly regulatable class L, the apparently unsophisti- 
cated class hl, and a regulatable class of intermediate 
complexity, inhibited by alanine and activated by 
Abbreviations. Fru-P,, fructose 1,6-bisphosphate; P-py- 
Enzyme. Pyruvate kinase (EC 2.7.1.40). 
ruvate, phosphoenolpyruvate. 
fructose 1,6-bisphosphate, which we propose to  
designate as class “A” because i t  was first observed 
in adipose tissue [911. Class A, rather than M as 
formerly reported, is the major component of the 
pyruvate kinase activity in kidney extracts and the 
minor one in liver extracts. A comparative study ofthe 
allosteric properties of the classes A and L from 
kidney and liver is also reported here. 
MATERIALS AND METHODS 
Wistar rats fed on a standard laboratory diet were 
used. Tissues were homogenized in the cold (2-4 “C) 
with 3 vol. of 0.25 M sucrose (except in the case of 
adipose tissue where 7 vol. was used) in a Kontes 
Dual-Grinder homogenizer, or, for the muscular 
tissues, a Virtk homogenizer. A sample of human liver 
from a surgical biopsy was obtained from Dr V. Rojo 
1 This grouping of isoenzymes in classes does not inter- 
fere with the recommendations of the IUPAC-IUB Commis- 
sion on Biochemical Nomenclature [lo] for the designation of 
individual isoenzymes. 
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(Centro Nacional de Investigaciones MBdico-Quirdrgi- 
cas de la Seguridad Social, Madrid). The homogenates 
were centrifuged at  30000 x g for 30 min. Ammonium 
sulphate fractionation of tissue extracts was carried 
out by addition, to  the latter, of a saturated solution 
of ammonium sulphate (at 2-4 "C, neutralized) to  
give the desired percentage saturations. The 30 to 
45O/, and the 55 -70°/,aaturation precipitates, collect- 
ed by centrifugation a t  20000 xg for 15 min, were 
dissolved in 25mM Tris-HC1 pH7.4 containing 
0.1 mM EDTA and 1 mM dithioerythritol and 
dialyzed for 2 h against the same mixture. The 30 to 
4501, fraction was routinely preincubated 5 min at 
38 "C just before assay [8]. 
Pyruvate kinase activity was assayed spectro- 
photometrically following the decrease in absorbance 
a t  340 nm, a t  room temperature (approx. 25 "C) 
in a reaction mixture containing, unless indicated 
otherwise, 60 mM imidazole-HC1 pH 7.0, 0.1 M KC1, 
5 mM MgCl,, 0.15 mM NADH, 1 mM MgADP, 1 U/ml 
lactate dehydrogenase, and 5 mM phosphoenol- 
pyruvate. Standard concentrations of potentially 
regulatory metabolites added were 2 mM for alanine 
and MgATP and 10 pM for FN-P,. 
Amino acids were of the L-series, unless indicated 
otherwise. They were obtained from Calbiochem, 
Mann, Fisher and Sigma. Muscle pyruvate kinase and 
auxillary enzymes were obtained from Boehringer. 
Nucleotides were obtained from Sigma, except CDP 
which was from Boehringer. 
RESULTS 
Effects of Abnine on the Pyruvate-Kimse Activity 
of Extracts and Fractions of Different Tissues 
While classL pymvate b a s e  is allosterically 
inhibited by both ATP and alanine [S], it was found 
that the enzyme from adipose tissue [9] and kidney 
extracts was strongly inhibited by alanine but not 
by ATP. A combination of alanine and cold pre- 
treatment [S] has led to the distribution of major 
tissues of the rat in three groups. As shown in Fig. 1, 
the pyruvate kinase activity in liver extracts is 
strongly inhibited by 2 mM alanine, a t  moderate 
concentrations of phosphoenolpyruvate if the extract 
is preincubated a t  37 "C before the assay; kidney 
and adipose tissue extracts are inhibited by alanine 
irrespective of temperature and skeletal muscle and 
brain (as well as heart and uterus) extracts are never 
inhibited by 2 mM alanine. 
Liver and kidney extracts were fractionated by 
precipitation with ammonium sulphate to separate 
the two isoenzymes known to occur in each of these 
tissues, and the fractions corresponding to the two 
isoenzymes were characterized with respect to 
allosteric properties by the use of a few purposely 
selected experimental conditions. The results in 
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Fig. I. Effects of the concentration of P-pyruaate, alanine, and 
cold pretreatment on the pyruvate kinme activity of certain rat 
tiawes. Extraction and assay as indicated in Materials and 
Methods. Extracts were prewarmed at  38 "C for about 5 min 
(triangles) or kept at  0 "C (circles) just until assay at  room 
temperature. Filled symbols: assay in the presence of 2 mM 
aianine; open symbols, without added alanine 
Table 1 show for the lower ammonium sulphate frac- 
tion a behaviour consistent with the allosteric prop- 
erties of pyruvate kinase L: (a) homotropic co- 
operativity for phosphoenolpyruvate, inhibition by 
(b) ATP and (c) alanine, and (d) activation by Fru-P,. 
In contrast, the higher ammonium sulphate fraction 
of both tissues, is inhibited by alanine but not by 
ATP, is activated by Fru-P,, and exhibits slight 
cooperativity with respect to phosphoerwlpyruvate 
in the absence of alanine. The effect of the concentra- 
tion of alanine on the inhibition of pyruvate kinase 
in the two higher ammonium sulphate fractions of 
liver and kidney and in tissue extracts is shown in 
Fig.2. In the three cases the effect of the concentra- 
tion of alanine on the activity with 0.5 mM phospho- 
erwlpyruvate reached 50°/,  inhibition at  about 0.lmM 
and was about g o o / ,  at 5 mM. These results suggest 
that the three cases involve the same type of regula- 
tory, isoenzyme of pyruvate kinase, which henceforth 
will be designated as class A. This conclusion is 
rcinforced by other kinetic parallelism between the 
major component of kidney extracts and the minor 
one of liver extracts that wil l  be reported below, but 
leaves quite open the possibility of each class involv- 
ing several individual isoenzymes that could differ 
in other properties. 
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Table 1. Kinetic characterization of the pyruvate kinuae isoenzymes in rat liver and kidney fractions 
Extract of rat liver and kidney were obtained and fractionated, and pyruvate kinase activity was assayed as described inMate- 
rials and Methods except for the concentrations of phosphoenolpyruvate (P-pyruvate) and effectors as indicated. All fractions 
were preincubated for about 5 min a t  37 "C just before essay. Resulta with the 55-70% fraction fmm liver in the presence of 
added Fru-P, were corrected for a small blank value caused by this metabolite with this aldolase-rich fraction 
Additions 
Liver Kidney 
30-45 55-70 '1. 30-45 o//p 55-70 'lo (NH,),SO, 
U/g tissm 
+ 
0.3 1.1 5 6 
+ Fru-P, addition, 10 pM - 
P-pyruvate, 0.1 mM 0.5 10 0.4 0.6 
P-pyruvate, 0.5 mM 7 11 0.8 0.9 1 .o 1.6 10 10 
P-pyruvate, 0.5 mM + alanine, 2 mM 0.5 12 0.2 0.9 0.1 1.3 1 9 
P-pyruvate, 0.5 mM + MgATP, 2 mM 1 13 0.6 0.7 0.4 1.4 10 10 
- + - - + 
P-pyruvate, 5 mM 12 13 1.2 1.1 2.0 2.2 12 13 
I 
100 
[L 
0 
0 0.5 1 .o  1 . 5  2.0 2 .5  5.0 
[Alanine] ( m M  ) 
Fig.2. Effect of the concentration of alanine on the activity of pyruvate kinase A from rat kidney, liver, and adipose tissue. 
55-70°/0 ammonium sulphate fractions of extracts from liver ( A ) ,  kidney (o), and adipose tissue (0) were obtained and 
assayed as indicated in Materials and Methods, with 0.5 mM phosphoenolpyruvate 
Time Course of the Inhibition 
by Ahnine and the Activation by Fru-P, 
of Pyruvate Kinas@ L and A 
Llorente et al. [S] showed that the strong inhibi- 
tion of pyruvate b a s e  L by ATP started without 
detectable lag and disappeared on removal of ATP 
with an enzymatic trap. Fig. 3 shows that the inhibi- 
tion of pyruvate kinases L and A by alanine and its 
counteraction by Fru- P, also appear and disappear 
very rapidly after addition and removal, respectively. 
The marked transition visible in the figure after the 
Fru-P, trap corresponds to the contribution of the 
enzymatic trap during the removal of Fru-P, ; because 
of the high affinity of the enzyme for Fru-P,, the 
initial rate of NADH disappearance is increased since 
the Fru-P, trap is acting before the pyruvate kinase 
runs short of activator. Observations of Hess and 
Kutzbach [ll] on electrophoretic behaviour of pyr- 
uvate kinase L that suggested the possibility of consid- 
erable hysteresis in the disappearance of the confor- 
mational change induced by Fru-P, should be abscrib- 
ed rather to the very high a fh i ty  of the enzyme for 
Fru- P,  when saturated with phosphoenolpyruvate. 
(B. Hess, personal communication). As previously 
emphasized for pyruvate kinase L [S], full activation 
of pyruvate kinase A, even in the presence of 
concentrations of alanine in the upper physiological 
range, can be achieved by ct concentration of Fru-P, 
as low as approx. 10 pM, within the physiological 
range of free Fru-P, in liver. 
Specificity of the Allosteric Inhibition 
by Alanine of Pyruvate Kinases L and A 
from Liver and Kidney 
The 20 amino acids common to proteins were 
tested as effectors of pyruvate kinases of classes L 
and A with preparations from both liver and kidney. 
From the results summarized in Table 2 it appears 
that there are three amino acids of particular interest: 
ctlanine, cysteine and phenylalanine. Stronger inhibi- 
tors than alanine are cysteine for pyruvate kinase L 
and phenylalanine for pyruvate kinase A. Some 
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Fig.3. Time course of the inhibition by alanine and the activu- 
tion by Pru-P, of pyruvate kinases L and A from rat liver. 
30-45°/0 (A) and 55-70°/, (B) ammonium sulphate frac- 
tions from rat liver, obtained as described in Materials and 
Methods, were used for pyruvate kinases of class L and A 
respectively. Pyruvate kinase activity was assayed in I as 
described in Materials and Methods, and in I1 after 5-min 
preincubation at 37 "C and with phosphoenolpyruvate a t  
0.5 mM in the case of class L and a t  0.2 mM in that of class A, 
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plus additions (in about 10-yl volumes) to give final molari- 
ties as indicated in brackets; the Fru-P, trap was a mixture 
of 2 U aldolaae, 10 U glycerol-3-phosphate dehydrogenase, 
and 60 U triosephosphate isomerase. Insert I11 is a test of 
the Fru-P, trap system without liver fraction; insert 111' 
is a test of the utilization of Fru-P, by the corresponding 
liver enzymes present in the 55-70°/, fraction, in the absence 
of added MgADP. The numbers accompanying lines indicate 
reaction rates in 103 (AA,,/min) 
Table 2. Inhibition by amino acids of the pyruvate kinuaes of claases L and A from rat liver and &hey 
30-45°/0 and 55-70°/, ammonium sulphate fractions of rat liver and kidney extracts, obtained as described in Materials and 
Methods, were used for classes L and A respectively and assayed with 0.5 mM P-pyruvate. The class L fractions were preincubat- 
ed 5 min a t  37 "C prior to assay. Results are expressed as a percentage of the activity of controls without added amino acids. 
Control values were per cuvette: 180 U and 95 U for class L from liver and kidney respectively, and 120 U for class A from both 
liver and kidney 
ChSB L Class A 
Amino acid added Liver Kidney Liver Kidney 
1mM 5mM ImM 5mM ImM 5 m M  ImM 5 m M  
Control 
Alanine 
Pheny lalanine 
Cysteine 
Valine 
Isoleucine 
Proline 
Methionine 
Glycine 
Serine 
Threonine 
Tyrosine 
Asn, Leu, 
Gln, Asp, 
Glu, Lys, 
Arg, His 
Tryptophan 
10 
70 
5 
85 
55 
- 
- 
- 
70 
80 
- 
O1. 
2 
45 
100 
2 
50 
70 
15 
85 
65 
55 
50 
60 
55 
> 70 
"0 "1. 
100 
20 5 
65 30 
25 15 
70 45 
65 15 
90 
80 70 
80 70 
75 60 
- - 
- - 
- 
- - 
"I. OIP 
100 
20 15 
15 5 
40 35 
70 40 
80 35 
60 20 
50 20 
60 25 
95 
- 120 
50 40 
75 45 
- 
> 70 
' l o  "lo 
100 
15 10 
10 5 
40 35 
85 45 
65 45 
55 40 
50 30 
55 40 
- 110 
45 40 
85 60 
- - 
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Fig.4. Effect of the concentration of cysteine on the activity of 
pyruvate kinase L from rat liver. A 30-45O/, ammonium 
sulphate fraction of rat liver extract was obtained and 
assayed as described in Materials and Methods, with 0.25 mM 
phosphoenolpyruvate and cysteine as indicated 
25 1 
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Fig.5. Effect 01 the concentration of phenylalanine on the 
actavity of pyruvate kinase A from rat kidney. A 55-70°/0 
ammonium sulphate fraction of rat liver extract was obtained 
and assayed as described in Materials and Methods, with 
0.5 mM phosphoenolpyruvate and phenylalanine as indicated 
Table 3. Effects of alanine, phenylalanine, cysteine, and 
mixtures of them on pyruvate kinases of classes L and A 
Experimental conditions as in Table 2. All amino acids were 
used a t  5mM concentrations. Results are expressed as a 
percentage of the activity of the controls 
Glass L Class A 
(liver) (kidney) Effectors 
O1. 01. 
None 100 100 
Alanine 4 18 
Cysteine 2 40 
34 
Phenylalanine 75 8 
Alanine + phenylalanine 4 
Alanine + cysteine - 
Phenylalanine + cysteine 2 20 
- 
Table 4. Stereospecificity of the danine effects on pyruvate 
kinases of classes L and M ,  as either an allosteric or an isosteric 
effectm respectively 
Enzyme preparations were obtained as indicahd in Materials 
and Methods. Class L was assayed as indicated in Materials 
and Methods, while classM was assayed by coupling to  
hexokinase (0.7 U) and glucose-6-phosphate dehydrogenase 
(1.5 U) with 1 mM glucose and 0.4 mM NADP. KCI was 
0.15 M except when testing the effect of pyruvate, which was 
used as the potassium salt. Activities are expressed as a 
percentago of controls 
Effector 
None 
L- Alanine 
n-Alanine 
L- Alanine 
D-Alanhe 
L-Alanine 
D-Alanine 
Pyruvate 
concn 
mM 
1 
1 
10 
10 
400 
300 
150 
Class L 
(from 
rat liver) 
0.5 mnl 
"0  
100 
21 
100 
( 5  
90 
- 
- 
- 
Class M 
(from rabbit muscle) 
2 mM 
mM P-pyruvate 
I P  "1. 
100 100 
- - 
- - 
52 100 
56 110 
11 69 
differences in apparent sensitivity according to the 
source of the enzyme preparation might not be signif- 
icant because of the probability of some contamina- 
tion, particularly with class A in the case of the 
lower ammonium sulphate fraction of rat kidney. 
The effect of the concentration of cysteine on the 
activity of pyruvate kinase L from rat liver is illus- 
trated in Fig. 4. At 0.25 mM phosphoenolpyruvate, 
as little as 0.06 mM cysteine is enough for 50°/, 
inhibition. The strong inhibition by cysteine is not 
shared by other compounds with free -SH groups, 
since neither dithioerythritol, glutathione, DL-homo- 
cysteine or even wcysteine, at 1 mM, were inhibitory 
in similar conditions. Fig.5 illustrates the strong 
inhibition of pyruvate kinase A by phenylalanine. 
The above three strongly inhibitory amino acids 
were assayed in pairs on the two classes of regulatory 
pyruvate kinases, as shown in Table 3. With pyruvate 
kinase L the strong inhibition by either cysteine or 
alanine were not appreciably affected by equimolar 
phenylalanine. Nevertheless, with pyruvate kinase A, 
equimolar mixtures of either phenylalanine or alanine 
with cysteine were less inhibitory than the former 
amino acids alone. These observations might contri- 
bute to the ascertaining of the number of amino acid 
regulatory sites, which wiU be discussed below. 
Differential stereospecificity eliminates the possi- 
bility that the inhibition by alanine of pyruvate 
kinases L and A could be related to the fact that 
alanine is a rather close structural analogue of the 
other product, pyruvate. The results in Table4 
indicate that alanine is indeed a potential isosteric 
inhibitor of pyruvate kinase, but that there are 
drastic differences both quantitative and qualitative 
between the strong and stereospecific inhibition of 
pyruvate b a s e  L (as well as that of type A, not 
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Table 5. Substrate and aElosteric specificity for nucleotides of 
pjruvate kinase L from rat liver 
A 30--45O/, ammonium wlpbate fraction of rat liver extract, 
obtained as described in Materials and Methods and virtually 
free of adenylate kinase, was used as enzyme preparation. 
Assays were carried out as indicated in Materials and Methods 
with substrates and effectors as indicated. Results are 
expressed in relative values, taking as 100 that obtained 
with the higher concentration of donor and acceptor substrate 
(B) Relative activities (A) Relative activities 
Nucleoside (with 0.25 mM 
Nucleoside (with 2.5 mM triphos- P-pyruvate and 
phates as 1 mM MgADP) 
inhibitors phates as 
substrates I -  5mM (5 &I) - Fru-P, + Bru-P1 
diphos- Pwruvate) 
10 pM 
None 35 70 
MgADP 86 100 MgATP 1 62 
MgADPa 29 69 MgGTPa 36 50 
MgUDPa 25 65 MgUTPa 19 19% 
MgCDPa 1 4 MgCTPa 22 66 
MgIDP 15 50 MgITP 26 72 
a To rule out or eliminate ATP impurities, yeast hexokinase (1.5 U) 
and 2-deoxyglucose (10mAf) were added to  the reaction mixture prior 
to pyruvate kinase. 
Raising the concentration of added Fru-P, to 0.1 mM did not 
affect the inhibition by UTP. 
included in the Table) by L-alanine. and the weak 
isosteric inhibition of pyruvate kinase M by either 
L- or D-alanine. The inhibitions by phenylalanine and 
cysteine are also stereospecific for the L-isomer and 
can be counteracted by low concentrations of Fru-Pz. 
Allosteric Inhibition 
of Pyruvate Kinuse L by ATP 
The strong inhibition by ATP of native pyruvate 
kinase L has been reported to  be an allosteric effect 
subject to reversible desensitization [S]. Nucleotide 
specilkity studies with the 30-45°/, ammonium 
sulphate fraction of rat liver, fully confirm this 
conclusion, since there is a marked difference between 
a wide specificity for nucleoside diphosphates as 
acceptors (ADP, GDP, UDP, and IDP) and a narrow 
one for Fru-P, reversible inhibition by nucleoside 
triphosphates, which is highly specific for ATP 
(Table 5). This observation fulfills a major require- 
ment of those outlined by Sols [I21 to  identify as 
allosteric certain effects by primary products. Al- 
though this allosteric inhibition can be reversed by 
increasing the concentration of phosphoenolpyruvate 
it is not related to the inhibition of muscle pyruvate 
kinase, well characterized by Reynard et aE. [13] as 
competitive respect to both ADP and phosphoenol- 
pyruvate because of steric hindrance on the active 
subsites. 
The lack of significant allosteric inhibition by 
ATP of 6he class A isoenzyme has been substantiated 
in several ways. Lowering the phosphoenolpyruvate 
concentration to 0.1 mM, while increasing the inhibi- 
tion of pyruvate kinase activity in a kidney extract 
by 2 mM alanine to about 95O/,, gave only a weak 
(..: 30°/,) inhibition by 2 mN ATP of total pyruvate 
kinase activity in the presence as well as in the 
absence of Fru-P,. In  mixtures of extracts of liver 
and kidney there was inhibition by ATP as expected 
for the proportion of pyruvate kinase L present in 
the mixtures. 
Effect of the Concentration of Phosphoenolpyruvate 
on the Activity of Pyruvate Kinme A after Different 
Treatments 
Total pyruvate kinase activity in kidney extracts, 
of which the major component belongs to class A a8 
shown above, gave nearly hyperbolic saturation 
curves for phosphoenolpyruvate with [S],., of 
= O . i  Mm. Nevertheless, after fractionation with 
ammonium sulphate the [S],., went up to 0.6mM. 
The results in Fig.6 indicate that the difference is 
related to the combined effect of the use of a cold 
buffer containing EDTA to dissolve the pyruvate 
kinase A after its precipitation with ammonium 
sulphate. I n  the absence of this treatment isolated 
pyruvate kinase A from rat kidney exhibited a K ,  
o i  0.1 mM. The increase in K,  induced by the EDTA- 
containing buffer can be reversed by preincubation 
of the preparation a t  37 "C. The EDTA-mediated 
effect is reminiscent of the observations of changes 
in behaviour of the pyruvate kinase in extracts of 
adipose tissue [14], a tissue that seems to contain 
pyruvate kinase of class A only [9]. 
Characterization of Classes L and A 
of Pyruvate Kinase in Human Liver 
A sample of human liver obtained by surgical 
biopsy was homogenized and the extract fractionated 
with ammonium sulphate essentially as indicated 
in Materials and Methods. Fig.7 gives the kinetic 
characterization of the 25 -45O/, ammonium sul- 
phate fraction. The following [S],., and n (Hill 
coefficient) values for phosphoenolpyruvate were 
calculated : without additions, 0.2 mM and 1.9 ; with 
2 mM MgATP, 0.4 mM and 3.3; with 2 mM alanine, 
0.7 mM and 3.6; with 2 mM cysteine, 1.1 mM and 
x4.0; and with 10pM Fru-PZ, (0.05mM. These 
results correspond to pyruvate kinase of the L class, 
as defined above. 
The kinetic characterization of the 55 -75O/, 
ammonium sulphate fraction is summarized in Table 6. 
The results clearly indicate that human liver, like 
that of the rat, contains, in addition to a class L 
pyruvate kinase, a class A isoenzyme which is allo- 
sterically inhibitable by alanine (and phenylalanine) 
but not by MgATP, and which is strongly activable 
by Fru-P,. 
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Pig. 6. Effects of EDTA and preincubation temperature on the 
activity of rat-kidney pyruvate kinase A at  different wncentra- 
twm of p h o s p h o e n o l p t e .  A 66-70°/0 ammonium sul- 
phate fraction of rat kidney was obtained and assayed as 
described in Materials and Methods, except that  the precipit- 
ated proteins were dissolved in either 0.25 M sucrose (open 
symbols) or in 50 mM Tris pH 7.4, 0.1 mM EDTA, 1 mM 
dithioerythritol, and assayed without (circles) or with 5-min 
preincubation at 37 "C (triangles) 
0.15 4 
1 2 3 5 
Fig. 7. Allosteric properties of class L lryruvate kinuse from 
human liver. A 25--45O/, ammonium sulphate saturation 
fraction of human liver was obtained and assayed as describ- 
ed in Materials and Methods, a t  different concentrations of 
phosphoenolpyruvate and with additions as follows: (0) no 
additions; ( 0 )  2 mM MgATP; (A) 2 mM alanine; (H) 2 mM 
cyateine; ( * )  10 pM Fm-P, 
[P  - pyruvate] ( r n M )  
DISCUSSION 
The increasing number of recognizable distinct 
forms of pyruvate kinase in animal tissues [15-171 
makes it convenient for studies of metabolic control 
at the enzyme level to group them in classes according 
to regulatory properties. The present work gives 
evidence that in higher animals there are a t  least 
three classes of isoenzymes of pyruvate kinase 
differing in regulatory properties in a well-defined 
and consistent pattern. These classes are not mere 
conformational varieties of a given isoenzyme [l I]. 
On the contrary, each of these classes includes, or 
might include, several different isoenzymes, even in 
Table 6. Allosteric daractei-izalion as class A of the pjmvate 
kinase activity in the 55--75O/, ammonium sulphate fraction 
of human liver 
A human liver sample was homogenized, fractionated and 
assayed essentially as described in Materials and Methods 
with 0.25 mM P-pyruvate and additions as indicated 
Inhibitors Fru-P, (lowM) Activity Effect (2 a) 
Ulmg ( O / J  
65 None - 
None + 13Eia activation (107) 
Alanine - 20b inhibition (67) 
Alanine + 130 
80 inhibition (85) Phenylalanine - 
67 no inhibition MgATP - 
Phenylalanine + 135 
% b, 0 Lowering the [Slo.s for P-pyruvate from (a) 0.4 to < 0.05 m3l 
b) to 0.8 mM and (c )  to 1.0 mM. 
the restricted sense of genetically determined 
differences in primary structure [lo]. 
Of the three classes, two have well-defined allo- 
steric properties suitable for metabolic control in 
physiological conditions. These two, the L and A 
classes, share a number of regulatory properties but 
difler in the allosteric inhibition by ATP, which 
occurs in class L but not in class A. ATP as a primary 
product of the pyruvate kinase reaction in its 
physiological direction is an isosteric inhibitor, as 
shown by Reynard et al. [13] with the muscle enzyme. 
The 1, class is not merely more sensitive to the same 
type of inhibition but has a specific mechanism for 
inhibition by ATP which is clearly allosteric on the 
basis of the convergence of the following criteria, 
among those outlined by Sols [lZ]: (a) it is indepen- 
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dent of the concentration of ADP ; (b) there is marked 
differential specificity, particularly with respect to 
the guanosine nucleotides; (c) the enzyme can be 
reversibly desensitized by standing in the cold; 
(d) it is counteracted by the allosteric effector Fru-P, 
and (e) it does not occur in enzymes from other 
sources such as, the M and A classes, as well as the 
yeast enzyme. Minor differences in reported Ki values 
for ATP between muscle pyruvate kinase and the 
non-L component in liver extracts [18] are not likely 
to  involve any s i g d c a n t  non-isosteric component. 
The difference between the A and the L classes of 
isoenzymes of pyruvate kinase implies more than the 
restriction to  the latter of the allosteric inhibition 
by ATP. Although these two regulatory isoenzymes 
are both allosterically inhibited by alanine within 
the physiological range of concentrations, there are 
marked differences in the specificity of inhibition by 
amino acids. Class L is more sensitive to inhibition 
by cysteine than by alanine and much less sensitive 
to phenylalanine, while class A is more strongly 
inhibited by phenylalanine and only weakly by 
cysteine. The results do not permit a conclusion as 
to  whether a single site with a different specificity 
pattern in each class of isoenzyme accounts for all 
these inhibitions or if two or three different amino 
acid inhibition sites are involved in each isoenzyme. 
The fact that serine is appreciably inhibitory for 
class LI, which is the ones tronglyinhibited by cysteine 
and the behaviour of mixtures of amino acids (Table 3) 
tend to suggest a site for cysteine in class L. Never- 
theless, some other type of information would be 
required to ascertain this matter. I n  any case, of 
these three amino acids only alanine is known to  
occur in liver a t  concentrations suitable for clearly 
important inhibitions in vivo [19--211. Carminatti 
and coworkers [22-241 and Tanaka and coworkers 
[16,17] have independently observed the strong 
inhibition by alanine of the non-L component of 
pyruvate kinase in liver and kidney extracts, The 
independent observation of Tanaka’s and Garminatti’s 
groups of certain regulatory properties of the non-L 
fraction of liver and kidney is reassuring. Their 
failure to  observe counteraction by Fru-P, of the 
inhibition by alanine of what we refer to as class A 
(Tanaka’s M,, Carminatti’s kidney I) suggests de- 
sensitization in their highly purified preparations. 
Pyruvate kinase L and A are not signi6cantly activat- 
ed by any of the protein amino acids, including 
histidine [25]. 
All available evidence indicates that  muscle 
pyruvate kinase is not a regulatory enzyme. The 
inhibition by phenylalanine described by Carminatti 
et al. [Z6] has concentration requirements and pH 
dependence orders of magnitude outside thc physio- 
logical range. From their data and the reported 
physiological concentration of phenylalanine in 
muscle of about 0.15 mM [27] the possible inhibition 
in vivo would be less than 501,. The signi6cance of 
the potential inhibition by phenylalanine of the 
pyruvate kinase M from muscle (the binding has 
been recently studied by Kayne and Price [ZS]), 
as well as that from brain [29], remains to be ascer- 
tained. Another marginal phenylalanine effect, the 
inhibition of the intestinal isoenzyme of alkaline 
phosphatase, has been shown to be neither regulatory 
nor allosteric [30] *. 
Alanine is the predominant amino acid going 
from muscle to liver in fasted animals [31], partly 
substituting for lactate in the classical Cori cycle. 
It has been characterized as a major precursor of 
carbon skeletons for gluconeogenesis [32,33]. Also, 
it has been found to be a powerful stimulant of gluca- 
gon secretion [24]. These facts make alanine a most 
suitable candidate for the negative control of pyr- 
uvate kinase activity essential to  prevent large-scale 
diversion of phosphoenolpyruvate in gluconeogenesis. 
We have no plausible explanation for the occur- 
rence of two different classes of allosteric, alanine- 
inhibitable, fructose-bis-phosphate-activatable pyr- 
uvate kinases in animal tissues, nor for the occurrence 
of a regulatable pyruvate kinase in non-gluconeogenic 
tissues. A similar problem concerns phosphoenol- 
pyruvate carboxykinase in these tissues. For adipose 
tissue the suggestion has been made that it could be 
related to glycerogencsis involving the lower part of 
the “gluconeogenic pathway”, although the large 
excess of pyruvate kinase makes unlikely an efficient 
control of its activity for such a purpose. And not 
even such a hypothetical role is apparent for the 
non-parenchymal cells of the liver, where the p p -  
uvate kinase seems to be also of class A [35,36]. It 
might not be fortuitous that there is apparent 
paralellism between the distribution of a regulatable 
pyruvate kinase and that of phosphoenolpyruvate 
carboxykinase, well characterized in adipose tissue 
and whose absence in skeletal muscle seems also well 
established. Glutamate, glutamine, aspartate and 
asparagine constitute about one fourth of the 
protein pool that can lead to  intermediate of the 
Krebs cycle through the action of glutamate dehydro- 
genase, glutamic oxalacetic transaminase, the urea 
cycle, and the purine nucleotide cycle [37]. For 
substantial use of these carbon skeletons for energy 
or fatty acid synthesis there is need of an ancillary 
pathway to  acetyl-CoA. The pair phosphoenolpyr- 
uvate carboxykinase -pyruvate kinase can insure 
such a conversion by an NADPH-independent system. 
One is tempted to speculate that once regulatable 
as well as non-regdatable classes of pyruvate kinase 
have been established in an organism, the former 
could be located in the genome in such relation to  
phosphoenolpyruvate carboxykinase that express- 
2The pyruvate kinase of Rhodotorula glutinks is not 
appreciably affected by phenylalanine at 10 mM (J. M. Gan- 
oedo, personal communication). 
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ibility of the latter in certain tissues would tend to 
be accompanied precisely by that of a regdatable 
pyruvate kinase, regardless of its ultimate value in 
a given tissue. In any case the occurrence of a regulat- 
able pyruvate kinase in these tissues might be useful 
to buffer the levels of glycolytic intermediate from 
Fru-P, to phosphoenolpyruvate. 
Pyruvate kinase activity in rat liver was shown 
to vary with nutritional conditions [38], the changes 
being due to variations in the level of the L isoenzyme 
[2]. In kidney, pyruvate kinase L behaves also as 
an adaptive enzyme (increased by high fructose 
diet), while class A does not change in either organ 
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